NME/NM23 family member 9Genealiases: NM23-H9 · NXL2 · TXL-2 · TXL2 · TXNDC6
Q-omics provides the consensus-scored NME9 profile across patient tissues and cancer cell-line models. NME9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NME9 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, NME9 RNA expression shows 21,114 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where NME9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME9 survival associations across molecular data types. NME9 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME9 RNA expression–survival associations across cancer types. High NME9 expression shows unfavorable associations in COAD and UVM, but favorable associations in BRCA, BLCA, KIRP and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NME9 RNA expression.
This table summarizes NME9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NME9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME9 shows lower tumor expression in KICH, LUSC, LUAD and THCA and higher tumor expression in BLCA and COAD. The KICH box plot shows higher NME9 RNA expression in normal versus tumor tissue (log2 FC = −0.948, t-test p < 0.001).
This table shows molecular features associated with NME9 in patient tissues and cancer cell lines. In patient samples, NME9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NME9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
